A retrospective cohort study found that patients with schizophrenia or bipolar I disorder who received long-acting injectable (LAI) antipsychotics had lower risks of disruptive life events and mortality compared with those receiving oral antipsychotics alone. The findings add to the growing evidence base on adherence and outcomes in real-world psychiatric care, where LAIs are often used to address missed dosing and relapse risk. For biotech and payer stakeholders tracking uptake drivers, the signal is notable because it links a formulation choice to downstream clinical and utilization endpoints rather than only symptom changes.